These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 24473428)
21. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963 [TBL] [Abstract][Full Text] [Related]
22. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687 [TBL] [Abstract][Full Text] [Related]
23. Contralateral recurrence of inflammatory myofibroblastic tumour of the lung 10 years after pneumonectomy. Vis DC; Kelly MM; Lee AG; Gelfand G; Johannson KA Thorax; 2018 Nov; 73(11):1089-1090. PubMed ID: 29884625 [No Abstract] [Full Text] [Related]
24. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979 [TBL] [Abstract][Full Text] [Related]
25. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391 [TBL] [Abstract][Full Text] [Related]
26. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370 [TBL] [Abstract][Full Text] [Related]
28. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273 [TBL] [Abstract][Full Text] [Related]
29. Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma. Muzahir S; Mian M; Munir I; Nawaz MK; Faruqui ZS; Mufti KA; Bashir H; Uddin N; Siddiqui N; Maaz AU; Mahmood MT Br J Radiol; 2012 Aug; 85(1016):e490-6. PubMed ID: 22215887 [TBL] [Abstract][Full Text] [Related]
30. [PET/CT in lymphoma patients]. Steinert HC Radiologe; 2004 Nov; 44(11):1060-7. PubMed ID: 15517141 [TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography for the staging of Hodgkin's lymphoma--increasing the body of evidence in favor of the method. Menzel C; Döbert N; Mitrou P; Mose S; Diehl M; Berner U; Grünwald F Acta Oncol; 2002; 41(5):430-6. PubMed ID: 12442918 [TBL] [Abstract][Full Text] [Related]
32. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369 [TBL] [Abstract][Full Text] [Related]